Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 139

  • 56

  • 22

  • 21

  • 21

  • 19

  • 14

  • 12

  • 10

  • 9

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Role of antigen-specific immunity in BCG therapy for bladder cancer

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Abstract
The gold standard immunologic agent for bladder cancer treatment is bacillus Calmette-Guérin (BCG), a live attenuated Mycobacterium. Repeated BCG instillations into bladder significantly reduce recurrence rates and offer an alternative to complete bladder removal. Unfortunately, the relapses occur and when BCG therapy fails, there are few options available. Despite decades of use, the mechanism for BCG efficacy remain largely unknown. Although it is established that T cells are required, the importance of tumor- vs BCG-specific immune response is unknown. Importantly, understanding how BCG augments antigen-specific immunity is critical to developing strategies to avoid BCG failure. We hypothesize that antigen-specific immunity contributes to clinical activity of BCG in bladder cancer. This hypothesis will be tested in the following aims that incorporate mouse models and patient samples to explore mechanisms underlying immune and clinical responses. Aim 1. Test the hypothesis that tumor-specific immunity contributes to BCG efficacy in bladder cancer. We will test effects of BCG on orthotopic bladder tumor-bearing mice by adoptive transfer of naïve vs tumor-specific T cells that we have developed. The effect of BCG on tumor-specific T cells will be corroborated using patient PBMCs before and after BCG treatment. Aim 2. Test the hypothesis that BCG-specific immunity contributes to BCG efficacy in bladder cancer. Similar to Aim 1, we will test BCG-specific T cells in bladder tumor-bearing mice treated with BCG. We will also enrich and transfer human BCG-specific T cells into human-tumor-challenged immune-deficient mice followed by intravesical BCG treatment. Summary: These studies will provide mechanistic insights into BCG efficacy in treating bladder cancer, and help establishing a framework for rapid development of BCG combination strategies for individual patients.

 
412
Projects
USD 226.8 M
Aggregated funding amount
USD 725 K
Average funding amount
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Alpha1H: A Unique Bladder Cancer Therapeutic, Acting with Great Precision

European Commission

USD 2,452,885
2020 - 2022
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Ciriaco A. Piccirillo, Jonathan David Spicer

USD 138,878
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy

National Cancer Institute to ANDREW TRUONG

USD 45,016
2020 - 2023
Project list item
A new bladder cancer model based on tissue reprogramming and gene targeting

National Cancer Institute to FLAMINIA TALOS, DAIFENG WANG

USD 203,843
2020 - 2021
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022
Project list item
Unravelling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

V Foundation for Cancer Research to Nicola J. Mason

USD 500,000
2019 - 2021
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

 
2019 - 2023
Project list item
[The association between SORL1 and advanced bladder cancer] - Original in Japanese

Japan Society for the Promotion of Science to Takanobu UTSUMI

USD 26,335
2019 - 2021
Project list item
Developing a SMART scaffold for bladder augmentation

National Institute of Biomedical Imaging and Bioengineering to GUILLERMO ANTONIO AMEER, JOHN ROGERS, ARUN SHARMA

USD 1,399,891
2019 - 2023
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
load more...